Cargando…

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer

Blockade of programmed cell death 1 ligand (PD-L1) has been used to treat triple-negative breast cancer (TNBC), and various strategies are under investigation to improve the treatment response rate. Inhibition of glutamine metabolism can reduce the massive consumption of glutamine by tumor cells and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Yuxia, Wang, Siqi, Li, Yang, Yuan, Chen, Zhang, Jie, Xu, Ziqing, Hu, Yongzhi, Shi, Haibin, Wang, Shouju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074360/ https://www.ncbi.nlm.nih.gov/pubmed/35524267 http://dx.doi.org/10.1186/s12951-022-01424-7

Ejemplares similares

A photodynamic-mediated glutamine metabolic intervention nanodrug for triple negative breast cancer therapy
por: Yu, Cancan, et al.
Publicado: (2023)

Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

Theranostic mesoporous platinum nanoplatform delivers halofuginone to remodel extracellular matrix of breast cancer without systematic toxicity
por: Zhang, Jie, et al.
Publicado: (2022)

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer
por: Qin, Ge, et al.
Publicado: (2020)

Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC)
por: Hong, Jiaxin, et al.
Publicado: (2022)

Glutamine metabolism regulates FLIP expression and sensitivity to TRAIL in triple-negative breast cancer cells
por: Mauro-Lizcano, Marta, et al.
Publicado: (2018)

Glutamine addiction promotes glucose oxidation in triple-negative breast cancer
por: Quek, Lake-Ee, et al.
Publicado: (2022)

Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer
por: Luo, Xiao, et al.
Publicado: (2021)

Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
por: Tashireva, Liubov A., et al.
Publicado: (2023)

GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer
por: Cheng, Shun-Wen, et al.
Publicado: (2021)

PKM2 promotes reductive glutamine metabolism
por: Liu, Miao, et al.
Publicado: (2018)

Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition
por: Lampa, Michael, et al.
Publicado: (2017)

PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
por: Alkaabi, Duaa, et al.
Publicado: (2023)

A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer
por: Wang, Chaoyang
Publicado: (2022)

Periodic Mesoporous Organosilica Coated Prussian Blue for MR/PA Dual‐Modal Imaging‐Guided Photothermal‐Chemotherapy of Triple Negative Breast Cancer
por: Tian, Wei, et al.
Publicado: (2016)

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies
por: Ma, Guofeng, et al.
Publicado: (2021)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

The risk of PD-L1 expression misclassification in triple-negative breast cancer
por: Ben Dori, Shani, et al.
Publicado: (2022)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer
por: Yang, Huijie, et al.
Publicado: (2022)

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
por: Barrett, Michael T., et al.
Publicado: (2018)

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
por: Chen, Xingyu, et al.
Publicado: (2022)

Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Yixi, et al.
Publicado: (2022)

Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)
por: Dobritoiu, Florin, et al.
Publicado: (2022)

Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth
por: Ye, Jianxin, et al.
Publicado: (2018)

The value of DCE- MRI of the breast as a diagnostic tool in assessing amorphous calcifications in screening mammography
por: Wang, Siqi, et al.
Publicado: (2023)

Natural Blockers of PD-1/PD-L1 Interaction for the Immunotherapy of Triple-Negative Breast Cancer-Brain Metastasis
por: Nakhjavani, Maryam, et al.
Publicado: (2022)

Glutamine deprivation plus BPTES alters etoposide- and cisplatin-induced apoptosis in triple negative breast cancer cells
por: Chen, Lian, et al.
Publicado: (2016)

MCT4/Lactate Promotes PD-L1 Glycosylation in Triple-Negative Breast Cancer Cells
por: Duan, Xianxian, et al.
Publicado: (2022)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
por: Qi, Yihang, et al.
Publicado: (2022)

Metabolic engineering of Escherichia coli for efficient production of l-alanyl-l-glutamine
por: Zhu, Jiangming, et al.
Publicado: (2020)

Coordinative metabolism of glutamine carbon and nitrogen in proliferating cancer cells under hypoxia
por: Wang, Yuanyuan, et al.
Publicado: (2019)

Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression
por: Xu, Pengfei, et al.
Publicado: (2021)

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
por: Sun, Woo Young, et al.
Publicado: (2016)

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
por: Shi, Shuai, et al.
Publicado: (2022)

Immunosuppression Induced by Glutamine Deprivation Occurs via Activating PD-L1 Transcription in Bladder Cancer
por: Wang, Liping, et al.
Publicado: (2021)

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
por: Zaslavsky, Alexander B., et al.
Publicado: (2020)

Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics
por: Huang, Xianghua, et al.
Publicado: (2021)

Editorial: Enhancing Drug Delivery and Tumor Penetration
por: Tang, Yuxia, et al.
Publicado: (2021)

Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
por: Gul, Samina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5r592cmp30nj2p6f2inu2l38nt